ATE135236T1 - Konjugate zur steigerung der durchlässigkeit der gefässe - Google Patents

Konjugate zur steigerung der durchlässigkeit der gefässe

Info

Publication number
ATE135236T1
ATE135236T1 AT89911955T AT89911955T ATE135236T1 AT E135236 T1 ATE135236 T1 AT E135236T1 AT 89911955 T AT89911955 T AT 89911955T AT 89911955 T AT89911955 T AT 89911955T AT E135236 T1 ATE135236 T1 AT E135236T1
Authority
AT
Austria
Prior art keywords
species
vasoactive
conjugates
disclosed
agent
Prior art date
Application number
AT89911955T
Other languages
English (en)
Inventor
Alan L Epstein
Michael M Glovsky
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE135236T1 publication Critical patent/ATE135236T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
AT89911955T 1988-10-11 1989-10-11 Konjugate zur steigerung der durchlässigkeit der gefässe ATE135236T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25551388A 1988-10-11 1988-10-11
US41778289A 1989-10-04 1989-10-04

Publications (1)

Publication Number Publication Date
ATE135236T1 true ATE135236T1 (de) 1996-03-15

Family

ID=26944744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89911955T ATE135236T1 (de) 1988-10-11 1989-10-11 Konjugate zur steigerung der durchlässigkeit der gefässe

Country Status (7)

Country Link
EP (1) EP0438497B1 (de)
JP (1) JP2961173B2 (de)
AT (1) ATE135236T1 (de)
AU (1) AU627785B2 (de)
DE (1) DE68925974T2 (de)
IL (1) IL91933A (de)
WO (1) WO1990003801A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0547163B1 (de) * 1990-08-29 2002-02-06 Centre Hospitalier Regional De Nantes An stabile proteinkernstruktur gebundene proteinpolyliganden
DE69133036T2 (de) * 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
AT409929B (de) * 1997-03-07 2002-12-27 Tritthart Helmut A Dr Polymere-infusionslösung zur anwendung bei der diagnose von tumoren, gegebenenfalls zu deren behandlung
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
CA2219961C (en) * 1998-01-09 2010-06-01 The University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
DE19824653A1 (de) * 1998-02-25 1999-08-26 Schering Ag Nekrose-affine Verbindungen und ihre Verwendung zur Herstellung von Präparaten zur Pharmakotherapie
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
EP1068224B1 (de) 1998-03-31 2005-05-11 Bristol-Myers Squibb Pharma Company Pharmazeutika zur bildgebung der angiogenischen krankheiten
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1140204A2 (de) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronektin-rezeptor antagonist arzeimittheln
US6630120B1 (en) * 1999-03-08 2003-10-07 Alkermes, Inc. Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
WO2001068679A2 (en) * 2000-03-16 2001-09-20 University Of Pittsburgh Peptides targeting specifically tumor-derived endothelial cells
IT1318485B1 (it) * 2000-04-21 2003-08-25 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi di ionimetallici nella visualizzazione diagnostica di sistemi microvascolari
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (de) 2001-05-03 2011-03-16 Merck Patent GmbH Rekombinanter, tumorspezifischer antikörper und dessen verwendung
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20060222653A1 (en) * 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
US12226758B2 (en) 2020-11-11 2025-02-18 Ningbo Institute Of Materials Technology And Engineering, Chinese Academy Of Sciences Raney copper catalyst as well as preparation method and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
WO1986003938A1 (en) * 1985-01-11 1986-07-17 The Regents Of The University Of California Method for preserving liposomes
US4724213A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
US4724212A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-2 and diagnostic antibody produced thereby
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4753895A (en) * 1987-02-24 1988-06-28 Hughes Aircraft Company Method of forming low leakage CMOS device on insulating substrate

Also Published As

Publication number Publication date
IL91933A (en) 1994-12-29
AU4424589A (en) 1990-05-01
EP0438497B1 (de) 1996-03-13
EP0438497A4 (en) 1992-02-26
AU627785B2 (en) 1992-09-03
WO1990003801A1 (en) 1990-04-19
DE68925974T2 (de) 1996-11-14
EP0438497A1 (de) 1991-07-31
DE68925974D1 (de) 1996-04-18
JP2961173B2 (ja) 1999-10-12
JPH04503945A (ja) 1992-07-16

Similar Documents

Publication Publication Date Title
ATE135236T1 (de) Konjugate zur steigerung der durchlässigkeit der gefässe
EP1704864B9 (de) Injizierbare Arzneimittelzubereitung bestehend aus einem Zytostatikum und einer durch einen Spacer gebundenen Maleinimidgruppe.
DE69010206D1 (de) Stabilisierte protein- oder peptidkonjugate.
Fiume et al. Drug targeting in antiviral chemotherapy: A chemically stable conjugate of 9-β-d-arabinofuranosyl-adenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells
EP0861667A3 (de) Partikelförmige Mittel
IL97411A (en) Pharmaceutical formulations comprising hapten-modified diagnostic or therapeutic agents
DE69812727D1 (de) Opioid-konjugate mit endogenen Trägerproteinen
DK651187A (da) Leveringsvehikel med amphiphil-associeret aktiv bestanddel og fremgangsmaade til dets fremstilling
WO1998022141A2 (en) Enhanced effects for hapten conjugated therapeutics
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
WO1997025097A3 (en) Activatable infusable dispersions and methods for using them for therapy and diagnostics
DE69129463D1 (de) Verwendung von substanzen in partikelform
CA2000479A1 (en) Vasopermeability-enhancing conjugates
Ely Dermatologic therapies you’ve probably never heard of
Gruber et al. An implantable pump for intrarenal infusion of immunosuppressants in a canine autotransplant model
AU754117B2 (en) Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells
RU94045008A (ru) Способ преодоления гематоэнцефалического барьера
JPH06293631A (ja) ケラチン加水分解物を担体として用いたドラッグデリバリーシステム
JPS60226819A (ja) フイブロネクチン複合体
SU1033141A1 (ru) Способ лечени деструктивного панкреатита
SU1037683A1 (ru) Способ получени модифицированной урокиназы
JPH04501705A (ja) 腫瘍の組み合せ処理のためのフィブリン溶解剤の使用
Hartmeier Uses in Medicine
TH51752A (th) องค์ประกอบของยาร่วมฤทธิ์และวิธีการสำหรับการบำบัดรักษาการเจริญเติบโตของเนื้องอกหรือมะเร็ง และสำหรับทำให้การสร้างเม็ดเลือดกลับดีขึ้น หรือการเพิ่มเม็ดเลือด

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties